Mind the Gap: bridging the translational gap in the management of schizophrenia by treating the whole person.

Main Article Content

Jacqueline Conway


Ever since the since the serendipitous discovery of the antipsychotic effect of chlorpromazine, the dopamine theory of schizophrenia has been the predominant one in both the understanding of its pathology and pharmacological management. Although this has had success in the management of positive symptoms of schizophrenia, this is not the case with negative symptoms of this disease. These are the ones which lead to the most long-term disability and consequent poor outcome. Pharmacological interventions for schizophrenia which concentrate on the dopaminergic pathways have had little success in alleviating negative symptoms of this disabling illness. Indeed, there has been a dearth of pharmacological initiatives addressing negative symptoms of schizophrenia.

Drug development seems to have been led by identifying and targeting a single explanatory mechanism for the disease. While each proposed explanatory mechanism has clear merits, each also has limitations. The most probable neuropathological explanation of schizophrenia is not confined to a single receptor or neural system, but the interaction of several dysfunctional ones. The especially aggressive nature of schizophrenia leads to a (variable) degree of cerebral tissue loss with each exacerbation of the illness. Understanding schizophrenia as a potentially neurodegenerative disease with neurodevelopmental antecedents may thus be a useful shift in the therapeutic appreciation of this illness. It is essential to remember that psychological and social factors also have neurological consequences: epigenetic influence is one way to understand the psychopathology of these consequences. This is, of course, the rationale for holistic treatment of the illness generally. The wide-ranging pathology of schizophrenia means that holistic management of it will always be required and the concentration on a single pathological pathway is one which both leads researchers to unrewarding conclusions and results in an unsatisfactory outcome for the person who suffers from schizophrenia. Successful management of this illness is therefore always holistic, including the maintenance of appropriate suitable medication as well as psychological and social interventions which are recovery focussed. A thorough understanding of all of the factors involved in schizophrenic illness therefore narrows the translational gap.

Article Details

How to Cite
CONWAY, Jacqueline. Mind the Gap: bridging the translational gap in the management of schizophrenia by treating the whole person.. Medical Research Archives, [S.l.], v. 8, n. 1, jan. 2020. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2028>. Date accessed: 14 may 2021. doi: https://doi.org/10.18103/mra.v8i1.2028.
Research Articles


1. Oliver D Howes and Shitij Kapur, 2009: The Dopamine Hypothesis of Schizophrenia: Version III-The Final Common Pathway Schizophrenia Bulletin 35 (3): 549-562

2. Albert C Yang and Shij-JenTsai. 2017: New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis International Journal of Molecular Sciences 18: 1689;
doi: 10.3390/ijms 18081689

3. Nancy C Andreasen, 2008: A Unitary Model of Schizophrenia: Bleuler’s “Fragmented Phrene” as Schizencephaly Archives of General Psychiatry 56: 781-787

4. Katie Solokowski and Joshua G Corbin, 2012: Wired for behaviors: from development to function of innate limbic system circuitry Frontiers in Molecular Neuroscience April 2012 5: 1-15
doi: 10.3389/fnmol.2012.00055

5. Daniel Bertrand, A V Terry Jr, 2018: The wonderland of neuronal nicotinic acetylcholine receptors Biochemical Pharmacology 151: 214-225; doi – 10.1016/j.bcp.2017.12.008

6. Dina Manetti, Cristina Bellucci, Niccolò Chiaramonte, Silvia Dei, Elisabeta Teodori& Maria Novewlli Romanelli, 2018: Designing selective modulators for the nicotinic receptor subtypes: challenges and opportunities Future Medicinal Chemistry 10 (4): 433-460

7. JP Kesby, DW Eyles, JJ McGrath and JG Scott, 2018: Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscienceTranslational Psychiatry 8:30 – 42
doi: 10.1038/s41398-017-0071-9

8. Sherry Leonard, Charles Breese, Catherine Adams, Khalid Benhammou, Judith Gault, Karen Stevens, Michael Lee, Lawrence Adler, Ann Olincy, Randal Ross, Robert Freedman, 2000: Smoking and schizophrenia: abnormal nicotinic receptor expression European Journal of Pharmacology 393 (1-3): 237-242

9. Alan R Sanders, Jubao Duan, Douglas F Levinson, Jianxin Shi, Deli He, Cuiping Hou, Gregory J Burrell, John P Rice, Deborah A Nertney, Ann Olincy, Pablo Rozic, Sophia Vinogradov, Nancy G Buccola, Brian J Mowry, Robert Freedman, Farooq Amin, Donald W Black, Jeremy M Silverman, William F Byerley Raymond R Crowe, C Robert Cloninger, Maria Martinez, Pablo Gejman, 2008: No Significant Association of 14 Candidate Genes With Schizophrenia in a Large European Ancestry Sample: Implications for Psychiatric Genetics American Journal of Psychiatry 165: 497-506

10. Emma C Johnson, Richard Border, Whitney E Melroy-Grief, Christiaan de Leeuw, Marissa A Ehringer and Matthew C Keller, 2017: No evidence that schizophrenia candidate genes are more associated with schizophrenia than non-candidate genes Biological Psychiatry 82 (10): 702-708;
doi 10.1016/j.biopsych.2017.06.033

11. Kathleen C Brown, Haley E Perry, Jamie K Lau, Dennie V Jones, Joseph F Pulliam, Brent A Thornhill, Clayton M Crabtree, Haitao Luo, Charlie Chen and Piyali Dasgupta, 2013: Nicotine Induces the Up-regulation of the α7-Nicotinic Receptor (α7-nAChR) in Human Squamous Cell Lung Cancer Cells via the Sp1/GATA Protein Pathway The Journal of Biological Chemistry 288 (46): 33049 – 33059;

12. Robert Freedman, Michael Hall, Lawrence E Adler, Sherry Leonard, 1995: Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia Biological Psychiatry 38 (1): 22-33

13. Magda Kondej, Piotr Stepnicki, Agnieska A Kaczor, 2018: Multi-Target Approach for Drug Discovery against Schizophrenia International Journal of Molecular Sciences 19 (10): 3105-3145;
doi: 10.3390/ijms 19 103 105

14. Selene R T Veerman, Peter F J Schulte, Lieuwe de Haan, 2017: Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review Drugs 77: 1423-1459

15. John W Olney, Hohn W Newcomer, Nuri B Farber, 1999: NMDA receptor hypofunction model of schizophrenia Journal of Psychiatric Research 33: 523-533

16. P W Chiu, Simon S Y Lui, Karen S Y Hung, Raymond C K Chan, Queenie Cahn, P C Sham, Eric F C Cheung, Henry K F Mak, 2018: In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study Schizophrenia Research 193: 295-303; doi: 10.1016/j.schres.2017.07.021

17. L Frederik Jarskog, 2006: Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations Current Opinion in Psychiatry 19: 307-312

18. JL Conway, 2009: Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications Medical Hypotheses 73 (2): 259-262; doi: 10.1016/j.mehy.2009.02.017

19. Gregory Dalack, Daniel J Healy, James H Meador-Woodruff, 1998: Nicotine Dependence in Schizophrenia: Clinical Phenomena and Laboratory Findings American Journal of Psychiatry 155: 1490-1501

20. A Takeda, E Loveman, A Clegg, J Kirby, J Picot E Payne and C Green, 2006: A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition quality of life and adverse events in Alzheimer’s disease International Journal of Geriatric Psychiatry 21: 17-28;
doi: 10.1002/gps.1402

21. Jeffrey Lieberman, Geoffrey Dunbar, Anthony C Segreti, Ragy R Girgis, Frances Seoane, Jessica S Beaver, NaihuaDuan and David A Hosford, 2013: A Randomised Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia Neuropsychopharmacology 38: 968-975

22. Lai Peng, Xiabo Zhong, 2015: Epigenetic regulation of drug metabolism and transport Acta Pharmaceutica Sinica B 5(2): 106-112

23. Lawrence E Adler, Ann Olincy, Merilyne Waldo, Josette G Harris, Jay Griffith, Karen Stevens, Karen Flack, Herbert Nagamoto, Paula Bickford, Sherry Leonard and Robert Freedman, 1998: Schizophrenia, Sensory Gating and Nicotinic Receptors Schizophrenia Bulletin 24(92): 189-202

24. Rezvani AH and Levin ED, 2001: Cognitive Effects of Nicotine Biological Psychiatry 49(3):258-267

25. Yuan Yuan Wang, Shuo Wang, Wei Zheng, Bao-Liang Zhong, Chee H Ng, Gabor S Ungvari, Chun-Xue Wang, Yu-Tao Xiang, Xiao-Hong Li, 2019: Cognitive functions in smoking and non-smoking patients with schizophrenia: A systematic review and metal analysis of comparative studies Psychiatry Research 272: 155-163

26. Ann Olincy, David A Young, Robert Freedman, 1997: Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers Biological Psychiatry 42 (1): 1-5

27. Veena Kumari, Peggy Postma, 2005: Nicotine use in schizophrenia: The self medication hypotheses Neuroscience and Biobehavioural Reviews 29@1021-1034

28. Dong-Dong Qin, Joshua Rizak, Xiao-Ii Feng, Shang-chuan Yang, Long-bao Lü, Lei Pan, Yong Yin & Xin-tian Hu, 2016: Prolonged secretion of cortisol as a possible mechanism underlying stress and depressive behaviour Scientific Reports 6: 30187; doi: 10.1038/srep30187

29. Jeffrey A Lieberman, 1999: Is Schizophrenia a Neurodegenerative Disorder? A Clinical and Neurobiological Perespective Biological Psychiatry 46: 729-739

30. Lauren M Hickling, Rocio Perez-Iglesias, Ann McNeill, Lynne Dawkins, John Moxha, Tamatha Ruffell, Kyra-Verena Sendt and Philip McGuire, 2018: A pre-post pilot study of electronic cigarettes to reduce smoking in people with severe mental illness Psychological Medicine 49(6): 1033-1040;
doi: 10.1017/S0033291718001782